Altimmune (ALT) Stock Price, News & Analysis

Company Overview

Altimmune, Inc. is a clinical‐stage biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies that harness the power of the immune system. The company’s research focuses on unmet medical needs in the fields of vaccines, liver disease and metabolic disorders. By leveraging its proprietary intranasal vaccine platform, Altimmune aims to deliver next‐generation products that improve efficacy, safety and patient compliance compared with traditional injectable formulations.

Altimmune’s lead vaccine candidate, NasoVAX™, is designed to protect against seasonal influenza by eliciting both systemic and mucosal immune responses following a single intranasal dose. The company is also advancing additional programs that apply its nasal delivery technology to respiratory pathogens, including a COVID‐19 vaccine candidate in early clinical testing. Beyond vaccines, Altimmune is developing immunotherapies for chronic liver conditions such as non‐alcoholic steatohepatitis (NASH) and is evaluating novel peptide‐based drugs aimed at addressing obesity and metabolic syndrome.

Founded in 2016 and headquartered in Gaithersburg, Maryland, Altimmune has built a robust development infrastructure with state‐of‐the‐art laboratories and manufacturing partnerships across North America and Europe. Since completing its initial public offering, the company has established strategic collaborations with academic institutions and biotechnology firms to accelerate preclinical research and streamline regulatory pathways. Altimmune’s multidisciplinary team works closely with global health authorities to design clinical trials that could support future product approvals.

Altimmune is led by a seasoned management team with extensive experience in drug development, regulatory affairs and commercialization. The executive leadership and board of directors bring together former senior executives from leading pharmaceutical companies and research institutions. This collective expertise positions Altimmune to advance its diversified pipeline toward pivotal trials and, ultimately, to bring innovative immune‐based products to patients worldwide.

Key Stats

• Today's Range: $4.10 to $4.35
• 50-Day Range: $3.50 to $7.71
• 52-Week Range: $2.90 to $11.16
• Volume: 4.15 million shs
• Average Volume: 3.37 million shs
• Market Capitalization: $335.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $18.20
• Consensus Rating: Moderate Buy

Altimmune Stock Analysis - MarketRank™

Altimmune scored higher than 45% of companies evaluated by MarketBeat, and ranked 642nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Altimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 5 buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Altimmune has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Altimmune are expected to grow in the coming year, from ($1.35) to ($0.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Altimmune is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Altimmune is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Altimmune has a P/B Ratio of 2.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

40.09% of the float of Altimmune has been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Altimmune has recently increased by 27.79%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Altimmune does not currently pay a dividend.

Dividend Growth

Altimmune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

40.09% of the float of Altimmune has been sold short.

Short Interest Ratio / Days to Cover

Altimmune has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Altimmune has recently increased by 27.79%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: 0.83

News Sentiment

Altimmune has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 13 news articles for Altimmune this week, compared to 6 articles on an average week.

Search Interest

51 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 96% compared to the previous 30 days.

MarketBeat Follows

10 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Altimmune insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.10% of the stock of Altimmune is held by insiders.

Percentage Held by Institutions

78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALT Stock Analysis - Frequently Asked Questions

How have ALT shares performed this year?

Altimmune's stock was trading at $7.21 at the start of the year. Since then, ALT shares have decreased by 42.6% and is now trading at $4.14.

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NASDAQ:ALT) issued its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.09. The firm earned $0.01 million during the quarter, compared to analyst estimates of $0 million. Altimmune had a negative trailing twelve-month return on equity of 65.44% and a negative net margin of 451,200.00%.
Read the conference call transcript.

When did Altimmune's stock split?

Shares of Altimmune reverse split on Friday, September 14th 2018.The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Altimmune's major shareholders?

Altimmune's top institutional investors include Baader Bank Aktiengesellschaft (0.04%) and Wealth Enhancement Advisory Services LLC (0.03%). Insiders that own company stock include Vipin K Garg, David Drutz, Matthew Scott Harris, Gregory L Weaver and Wayne Pisano.
View institutional ownership trends.

How do I buy shares of Altimmune?

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 7/13/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALT
• CIK: 1326190
• Web: altimmune.com
• Phone: (240) 654-1450
• Fax: 410-269-2601
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Altimmune: $18.20
• High Price Target: $26.00
• Low Price Target: $12.00
• Potential Upside/Downside: +339.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.75
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$95.06 million
• Net Margins: -451,200.00%
• Pretax Margin: -454,604.97%
• Return on Equity: -65.44%
• Return on Assets: -58.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.85
• Quick Ratio: 15.85

Sales & Book Value

• Annual Sales: $20 thousand
• Price / Sales: 16,789.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: 2.38

Miscellaneous

• Outstanding Shares: 81,110,000
• Free Float: 77,782,000
• Market Cap: $335.80 million
• Optionable: Optionable
• Beta: 0.47